Recent
Press Releases:
- Aug 22, 2008
- Feb 11, 2008
- Jan 25, 2008
- Jan 24, 2008
- Jan 17, 2008
- Jan 11, 2007
- Nov 15, 2006
- Oct 2, 2006
- Jul 5, 2006
- Apr 4, 2006
- Feb 16, 2006
- Jan 24, 2006
- Sep 14, 2005
- Aug 9, 2005
- May 13, 2005
- May 4, 2005
- March 22, 2005
Upcoming Events |
OFFICIAL RELEASE
Ash Access Technology, Inc. Appoints Carmine J. Durham Vice President
of Sales, Marketing and Business Development
Former Bone Care International Executive Brings Highly Successful
Pharmaceutical and Biotech Experience
Tuesday, August 9, 2005 3:50
PM EST - - - (Lafayette, Indiana) Ash
Access Technology, Inc., an emerging leader in vascular access devices
and the prevention of catheter-related bloodstream infections (CRBSI),
announced today the appointment of Carmine
J. Durham to the position
of Vice President, Sales, Marketing and Business Development.
"We believe that Mr. Durham’s extensive experience in
strategic marketing and product commercialization with leading pharmaceutical
companies, (most recently Bone Care International, which was acquired
by Genzyme Corporation in July of this year for over $600 million)
is a distinct asset to our company," says Bob Truitt, President
and CEO, Ash Access Technology, Inc. "As we bring our flagship
product, AAT-023 (a novel antimicrobial / antithrombotic solution
for the prevention of catheter-related bloodstream infection the
eradication of biofilm), as well as our emerging vascular access
devices to a global market, Mr. Durham's background will be invaluable.
Not only do we have exceptional products working through our development
pipeline, but we continue to build an exceptional team. We are excited
to have a person with Carmine’s depth of experience and track
record of success leading our market development activities.”
Most recently, Mr. Durham served as Vice President of Corporate
Development and Strategy at Bone Care International where he played
a key role in investor relations, corporate strategy and building
value for the organization leading up to its recent merger with Genzyme.
In prior roles, Mr. Durham was Vice President, Marketing at Bone
Care, Business Unit Director at Abbott Laboratories, Director of
Marketing at Knoll-BASF Pharma and held progressive sales and marketing
leadership positions at Knoll-BASF Pharma, Boehringer Mannheim Corporation
and Merck. Mr. Durham is a 1988 graduate of the University of New
Mexico and has been active in a variety of biotech and medical professional
organizations.
"I am very excited about the opportunity to join Ash Access
Technology, particularly as we approach the pivotal clinical trial
for AAT-023 in chronic kidney disease (CKD) patients on dialysis
and finalize designs on our catheter-related technologies," said
Carmine Durham. “With novel products like AAT-023, Ash Access
is well positioned to become a leader in the emerging field of infection
prevention by providing clinicians with innovative products designed
to improve clinical outcomes and the quality of their patients lives.”
Ash Access Technology, Inc. is a privately-held
company founded to develop antimicrobial and vascular access technologies,
devices and methodologies to combat the deadly and expensive problem
of catheter-related bloodstream infections (with an emphasis on prevention).
Dr. Stephen R. Ash, Chairman and Director, Research and Development,
is a practicing Nephrologist with the Arnett Clinic in Lafayette,
Indiana, and is a world-recognized researcher and patent holder in
extracorporeal devices, sorbent chemistry, and vascular and peritoneal
access devices. Ash Access Technology is located in Lafayette, Indiana
in the INOK Business Center.
This press release contains forward-looking statements, which if
not based on historical facts, involve risks and uncertainties. Our
actual results may differ materially from the results or events stated
in the forward-looking statements, including, but not limited to,
certain events not within the Company's control. |